Viking Therapeutics (VKTX)
26.38
-0.33 (1.24%)
Upcoming Events
Latest Headlines
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
October 21, 2026 4:05 PM - PR NewsWire
Viking Therapeutic (VKTX) PT Lowered to $106 at Canaccord
October 20, 2026 6:44 AM - StreetInsider
UBS Starts Viking Therapeutic (VKTX) at Buy
October 14, 2026 4:32 PM - StreetInsider
Viking Therapeutics starts Phase 3 trials for oral obesity drug VK2735
October 14, 2026 7:05 AM - StreetInsider
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
October 14, 2026 7:05 AM - PR NewsWire
Viking Therapeutic (VKTX) PT Lowered to $85 at Truist Securities
October 7, 2026 7:14 AM - StreetInsider
Viking Therapeutics starts oral VK2735 maintenance dosing trial
October 6, 2026 7:06 AM - StreetInsider
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
October 6, 2026 7:05 AM - PR NewsWire
Form 8-K Viking Therapeutics, For: Sep 23
September 28, 2026 5:27 PM - SEC Filing
Viking Therapeutics raises $575M through stock and note offerings
September 28, 2026 4:30 PM - StreetInsider
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Co
September 28, 2026 4:30 PM - PR NewsWire
Form 424B5 Viking Therapeutics,
September 25, 2026 6:02 AM - SEC Filing
Form 424B5 Viking Therapeutics,
September 25, 2026 6:02 AM - SEC Filing
One investor reportedly took a third of Viking’s share sale
September 24, 2026 2:04 PM - StreetInsider
Viking share sale investor said to be allocated a third of deal -Bloomberg
September 24, 2026 1:11 PM - StreetInsider
Viking Therapeutics prices $500M stock and convertible notes offering
September 24, 2026 7:05 AM - StreetInsider
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
September 24, 2026 7:05 AM - PR NewsWire
Form FWP Viking Therapeutics, Filed by: Viking Therapeutics, Inc.
September 24, 2026 6:08 AM - SEC Filing
Form 305B2 Viking Therapeutics,
September 24, 2026 6:02 AM - SEC Filing
Form 424B5 Viking Therapeutics,
September 23, 2026 5:13 PM - SEC Filing
Form 424B5 Viking Therapeutics,
September 23, 2026 5:13 PM - SEC Filing
Viking Therapeutics plans $400M raise via stock and note offerings
September 23, 2026 4:33 PM - StreetInsider
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
September 23, 2026 4:33 PM - PR NewsWire
Viking Therapeutic (VKTX) PT Raised to $87 at Truist Securities
September 23, 2026 7:10 AM - StreetInsider
Viking Therapeutics (VKTX) call put ratio 2.4 calls to 1 put with a focus on September 25 weekly calls as share price up 31%
September 22, 2026 2:40 PM - StreetInsider
Goldman Sachs on Viking Therapeutic (VKTX): 'we believe these results look encouraging'
September 22, 2026 1:07 PM - StreetInsider
B.Riley: 'We are aggressive buyers of Viking Therapeutics'
September 22, 2026 10:35 AM - StreetInsider
Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals
September 22, 2026 10:32 AM - StreetInsider
Form 8-K Viking Therapeutics, For: Sep 22
September 22, 2026 7:06 AM - SEC Filing
Viking Therapeutics reports VK2735 weight maintenance data with less frequent dosing
September 22, 2026 7:05 AM - StreetInsider
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
September 22, 2026 7:05 AM - PR NewsWire
Oppenheimer Reiterates Outperform Rating on Viking Therapeutic (VKTX)
September 21, 2026 5:11 AM - StreetInsider
B.Riley on Viking Therapeutic (VKTX): 'we continue to see an attractive setup'
September 8, 2026 1:20 PM - StreetInsider
Viking Therapeutics (VKTX) PT Lowered to $65 at JPMorgan
August 11, 2026 8:49 AM - StreetInsider
Form 4 Viking Therapeutics, For: Aug 01 Filed by: Kelly-Gemmell Dorothy Elizabeth
August 7, 2026 4:35 PM - SEC Filing
Form 3 Viking Therapeutics, For: Aug 01 Filed by: Kelly-Gemmell Dorothy Elizabeth
August 7, 2026 4:34 PM - SEC Filing
Viking Therapeutic (VKTX) PT Raised to $114 at Canaccord
July 30, 2026 7:21 AM - StreetInsider
Viking Therapeutics (VKTX) files mixed shelf
July 30, 2026 6:08 AM - StreetInsider
Form S-3ASR Viking Therapeutics,
July 30, 2026 6:04 AM - SEC Filing
Form 4 Viking Therapeutics, For: Jul 28 Filed by: Lian Brian
July 29, 2026 8:07 PM - SEC Filing
Form 4 Viking Therapeutics, For: Jul 28 Filed by: ZANTE GREG
July 29, 2026 8:07 PM - SEC Filing
Form 4 Viking Therapeutics, For: Jul 28 Filed by: Mancini Marianna
July 29, 2026 8:06 PM - SEC Filing
Form 10-Q Viking Therapeutics, For: Jun 30
July 29, 2026 5:16 PM - SEC Filing
Viking Therapeutics (VKTX) Tops Q2 EPS by 13c
July 29, 2026 4:30 PM - StreetInsider
Form 144 Viking Therapeutics, Filed by: Lian Brian
July 29, 2026 4:19 PM - SEC Filing
Form 8-K Viking Therapeutics, For: Jul 29
July 29, 2026 4:06 PM - SEC Filing
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
July 29, 2026 4:05 PM - PR NewsWire
Form 144 Viking Therapeutics, Filed by: ZANTE GREG
July 29, 2026 4:05 PM - SEC Filing
Form 144 Viking Therapeutics, Filed by: Mancini Marianna
July 29, 2026 4:03 PM - SEC Filing
Viking Therapeutics adds Dorothy Gemmell to its board of directors
July 23, 2026 7:05 AM - StreetInsider
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
July 23, 2026 7:05 AM - PR NewsWire
Full Article List
